Research Platform for Head and Neck Squamous Cell Carcinoma to Study Molecular and Blood Biomarkers, Treatments, and Outcomes in Patients Receiving Palliative Care

What this Trial Is About

This research aims to create a detailed clinical registry platform to reflect real-world treatment patterns for patients with recurrent or metastatic head and neck tumors, including squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. The study seeks to understand molecular and blood-based biomarkers and treatment outcomes to improve therapy strategies in this patient population where new treatments like checkpoint inhibitors have changed care approaches. Participants will be observed without intervention, with data collected on demographics, social history, risk factors, medical and family history, disease and treatment course, molecular pathology results, treatment details, response rates, progression-free survival, and overall survival. The study is designed to be flexible and modular, enabling integration of new research questions and assessments, such as molecular testing, over time to keep pace with evolving treatment standards. During participation, patients clinical data will be continuously gathered and analyzed over a period of three years, focusing on sociodemographic factors, treatment decisions, response rates, progression, and survival outcomes. This observational study involves patients receiving palliative systemic treatment or best supportive care and aims to provide insights into treatment sequences and outcomes in real-world settings, including rare tumor types. The total follow-up duration for outcome assessment is three years.

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome